Francesca Lorraine Wei Inng Lim
Overview
Explore the profile of Francesca Lorraine Wei Inng Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan C, Loh J, Sin W, Teo D, Tan N, Nagarajan C, et al.
Mol Ther Nucleic Acids
. 2025 Feb;
36(1):102444.
PMID: 39897577
Nucleic acid amplification tests (NAATs) have enabled fast and sensitive detection of virus infections but are unable to discriminate between live and dead/inert viral fragments or between latent and reactivated...
2.
Ng L, Ong S, Huang X, Ghosh A, Nagarajan C, Goh Y, et al.
Leuk Lymphoma
. 2024 Dec;
:1-7.
PMID: 39731562
The importance of extra-nodal disease has been well recognized in follicular lymphoma, and is incorporated into various prognostic tools. However, the optimal treatment strategy for this subgroup remains unclear. In...
3.
Lim R, Tan J, Tan Y, Heng Z, Ng L, Lim F, et al.
Ann Hematol
. 2024 Nov;
103(12):5483-5493.
PMID: 39542909
Background: Recent breakthrough advances in the treatment of DLBCL, such as the antibody-drug conjugate polatuzumab vedotin, have yielded clinical survival benefit over rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for...
4.
Sin W, Jagannathan N, Teo D, Kairi F, Fong S, Tan J, et al.
Nat Biomed Eng
. 2024 Jun;
8(12):1571-1591.
PMID: 38834752
The manufacturing of autologous chimaeric antigen receptor (CAR) T cells largely relies either on fed-batch and manual processes that often lack environmental monitoring and control or on bioreactors that cannot...
5.
Huang X, Gan G, Chan E, Heng K, Perumal S, Salleh R, et al.
Haematologica
. 2023 May;
108(11):3131-3134.
PMID: 37165850
No abstract available.
6.
Ong S, Chen Y, Tan M, Ho A, Hwang W, Lim F
Eur J Haematol
. 2023 Mar;
112(2):144-152.
PMID: 36987995
Although chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in patients with chemo-refractory B-cell lymphoma, a significant portion is refractory or relapse. Resistance is a major barrier to...
7.
Tong L, Lim E, Yeo S, Hou A, Linn Y, Ho A, et al.
Ophthalmol Ther
. 2023 Mar;
12(3):1547-1567.
PMID: 36856978
Introduction: To profile conjunctival T cell populations in allogeneic hematopoietic stem cell transplant (HSCT) patients after instillation of daily topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis), and to evaluate patients'...
8.
Imahashi N, Basar R, Huang Y, Wang F, Baran N, Banerjee P, et al.
J Immunother Cancer
. 2022 Dec;
10(12).
PMID: 36543374
Background: B cells play a pivotal role in regulating the immune response. The induction of B cell-mediated immunosuppressive function requires B cell activating signals. However, the mechanisms by which activated...
9.
Lim F, Yunxin C, Huang F, Hwang W
Hematol Oncol
. 2022 Sep;
40 Suppl 1:4-12.
PMID: 36047631
Novel therapeutic options for cancer offer hope for patients and their families, particularly when the cancer has not responded to established treatment regimens. The CAR-T cell therapeutic approach has changed...
10.
Lim F, Yunxin C, Huang F, Hwang W
Hematol Oncol
. 2022 Aug;
PMID: 35951479
Novel therapeutic options for cancer offer hope for patients and their families, particularly when the cancer has not responded to established treatment regimens. The chimeric antigen receptor (CAR)-T cell therapeutic...